Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,833.43
(
-0.20%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tika1 post# 222990

Wednesday, 05/08/2019 10:56:17 AM

Wednesday, May 08, 2019 10:56:17 AM

Post# of 257382
PTLA’s Bevyxxa sales continue to be negligible:

https://www.globenewswire.com/news-release/2019/05/08/1819333/0/en/Portola-Pharmaceuticals-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html

1Q19 Bevyxxa sales were $77,000 (not a typo).

Andexxa sales are not exactly on fire either: 1Q19 sales were $20.3M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up